Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

PJ34

Catalog No: tcsc1463

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
344458-19-1

Formula:
$C_{17}H_{17}N_3O_2$

Pathway:
Epigenetics;Cell Cycle/DNA Damage

Target:
PARP;PARP

Purity / Grade:
>98%

Solubility:
DMSO : 30 mg/mL (101.58 mM; Need ultrasonic and warming)

Observed Molecular Weight:
295.34

Product Description

PJ34 is a potent specific inhibitor of **PARPI/2** with **IC_{50}** of 110 nM and 86 nM, respectively.

IC50 & Target: IC50: 110 nM (PARP1), 86 nM (PARP2)[1]

In Vitro:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

PJ34 inhibits the PARP enzyme activity with an IC_{50} of 110±1.9 nM. To compare the neuroprotective properties of other PARP inhibitors in PC12 cells, PJ34 is evaluated using by LDH assay. PJ34 treatment also significantly and concentration dependently attenuates cell death at a concentration ranging from 10^{-7} to 10^{-5} M[1].

In Vivo: To compare the potency and efficacy with other PARP inhibitors, PJ34 is evaluated at the doses of 3.2 and 10 mg/kg, respectively. PJ34 at the dose of 3.2 mg/kg significantly reduces cortical damage by 33%; however, 10 mg/kg dosing shows reversed effect (17% reduction)[1]. PJ34 (25 mg/kg) reduces the levels of TNF-α mRNA in ischemic animals by 70% and these values in treated mice do not differ from that of sham or naive animals. Treatment of ischemic mice with PJ34 reduces the level of E-selectin mRNA by 81% and that of ICAM-1 mRNA by 54%, compared to vehicle-treated ischemic mice[2].